Best Dividend Stocks to Invest in 

1. Coca-Cola (KO)

Sector: Consumer Defensive | Exchange: NYSE

Coca-Cola is one of the most widely held dividend stocks in the world, and for good reason. The company operates in over 200 countries, holds an Altman Z-Score of 4.71, and is rated Resilient for capital management.

Dividend Data

• Annual Dividend: $2.04 per share

• Dividend Yield: 2.65%

• Ex-Dividend Date: 13 March 2026

• Payment Date: 1 April 2026

Valuation
The average fair value is $81.92. At a current price of $77.04, the stock trades 6.33% below that fair value, making it one of the more attractively priced entries on this list.

Financial Health
Profit margin stands at 27.81%, return on equity at 41.86%, and the Beneish M-Score of -3.05 indicates no evidence of earnings manipulation. Revenue has grown from $43.0 billion in 2022 to $47.06 billion in 2024.

Why It Suits Long-Term Dividend Investors
Coca-Cola has one of the most durable brand moats in consumer goods. Consistent revenue growth, strong pricing power, and a global distribution network support reliable dividend payments over decades.

2. Johnson & Johnson (JNJ)

Sector: Healthcare | Exchange: NYSE

Johnson & Johnson is a global pharmaceutical and medical technology company with a market capitalisation of $583.84 billion. It holds an Altman Z-Score of 5.45, the highest on this list, and is rated Resilient.

Dividend Data

• Annual Dividend: $5.20 per share

• Dividend Yield: 2.16%

• Ex-Dividend Date: 24 February 2026

• Payment Date: 10 March 2026

Valuation
The average fair value is $229.26. At a current price of $240.40, the stock trades approximately 4.63% above fair value, suggesting modest overvaluation at present levels.

Financial Health
Revenue grew from $79.99 billion in 2022 to $88.82 billion in 2024. Profit margin is 18.79%, return on equity is 20.06%, and the debt-to-equity ratio is a conservative 0.43. The Beneish M-Score of -2.7 indicates clean financial reporting. Recent director purchases further signal internal confidence.

Why It Suits Long-Term Dividend Investors
JNJ has raised its dividend for over 60 consecutive years. The combination of a low debt load, strong margins, and healthcare sector resilience makes it a cornerstone holding for income-focused portfolios.

3. Realty Income (O)

Sector: Real Estate | Exchange: NYSE

Realty Income, known as "The Monthly Dividend Company," is a REIT that pays dividends monthly rather than quarterly. It is a constituent of the S&P 500 and MSCI World indexes.

Dividend Data

• Annual Dividend: $3.50 per share

• Dividend Yield: 5.38%

• Ex-Dividend Date: 27 February 2026

• Payment Date: 13 March 2026

Valuation
The average fair value is $59.91. At a current price of $65.00, the stock trades 7.83% above fair value. The DCF model indicates a significantly higher intrinsic value of $107.40, providing a contrasting bullish case.

Financial Health
Revenue has grown from $4.08 billion in 2023 to $5.75 billion in 2025. The profit margin is 20.09%. The Altman Z-Score of 0.02 is low, though this metric is less reliable for REITs given their capital structure. The Piotroski F-Score of 6 and Beneish M-Score of -2.51 are both reassuring.

Why It Suits Long-Term Dividend Investors
Monthly dividend payments and a 5.38% yield make Realty Income one of the most income-friendly options on this list. Investors should note the REIT's higher leverage profile and focus on the long-term revenue growth trajectory when assessing its durability.

4. PepsiCo (PEP)

Sector: Consumer Defensive | Exchange: NASDAQ

PepsiCo is a global food and beverage company with a portfolio that spans carbonated drinks, sports nutrition, and snacks. It is rated Resilient and holds an Altman Z-Score of 3.73.

Dividend Data

• Annual Dividend: $5.62 per share

• Dividend Yield: 3.53%

• Ex-Dividend Date: 6 March 2026

• Payment Date: 31 March 2026

Valuation
The average fair value is $145.66. At a current price of $159.43, the stock trades 8.64% above fair value. Long-term investors may prefer to wait for a pullback before initiating a position.

Financial Health
Revenue reached $93.93 billion in 2025. Return on equity is 42.86% and the Altman Z-Score of 3.73 indicates low bankruptcy risk. The debt-to-equity ratio of 2.07 reflects the use of leverage common in large consumer staples companies.

Why It Suits Long-Term Dividend Investors
PepsiCo has increased its dividend for over 50 consecutive years. Its dual exposure to beverages and snacks provides broader revenue diversification than pure-play beverage peers, supporting dividend stability through varying economic conditions.

5. Abbott Laboratories (ABT)

Sector: Healthcare | Exchange: NYSE

Abbott Laboratories develops and manufactures medical devices, diagnostics, nutritional products, and established pharmaceuticals. It holds a market capitalisation of $191.40 billion and is rated Resilient.

Dividend Data

• Annual Dividend: $2.40 per share

• Dividend Yield: 2.19%

• Ex-Dividend Date: 15 April 2026

• Payment Date: 15 May 2026

Valuation
The average fair value is $140.68. At a current price of $109.56, the stock trades 28.41% below fair value, the largest valuation discount on this list. The DCF model supports this with a fair value estimate of $99.39, while the Peter Lynch and EVA models indicate $168.99 and $173.73 respectively.

Financial Health
Profit margin is 16.72%, return on equity is 31.07%, and the debt-to-equity ratio is a low 0.26. The Altman Z-Score of 5.35 indicates very low bankruptcy risk. The Piotroski F-Score of 7 reflects strong and improving financial fundamentals. Recent insider purchases by both the CEO and a director reinforce the undervaluation thesis.

Why It Suits Long-Term Dividend Investors
Abbott has raised its dividend for over 50 consecutive years and offers a meaningful discount to estimated fair value. High switching costs in medical devices and a broad patent portfolio support durable earnings and dividend growth.

6. AbbVie (ABBV)

Sector: Healthcare | Exchange: NYSE

AbbVie is a global biopharmaceutical company specialising in immunology, oncology, aesthetics, and neuroscience. It holds a market capitalisation of $409.69 billion and is rated Resilient.

Dividend Data

• Annual Dividend: $6.65 per share

• Dividend Yield: 2.89%

• Ex-Dividend Date: 15 April 2026

• Payment Date: 15 May 2026

Valuation
The average fair value is $165.59. At a current price of $230.11, the stock trades 28.04% above fair value. This is a notable premium and warrants caution for investors prioritising entry price discipline.

Financial Health
The Beneish M-Score of -2.75 indicates no signs of earnings manipulation. The Altman Z-Score of 2.31 places the company in the moderate risk zone, influenced by the company's high debt load following its Allergan acquisition. Return on equity is 62.52%, reflecting strong profitability from its shareholder equity base.

Why It Suits Long-Term Dividend Investors
AbbVie has grown its dividend significantly since its 2013 spin-off from Abbott. The transition from Humira to next-generation drugs Skyrizi and Rinvoq is progressing. The Botox and Juvederm aesthetics franchise provides a durable revenue stream independent of pharmaceutical patent cycles.

7. NextEra Energy (NEE)

Sector: Utilities | Exchange: NYSE

NextEra Energy is the largest regulated electric utility in the United States by market capitalisation and is recognised as a global leader in wind and solar energy generation. It holds a market capitalisation of $190.14 billion.

Dividend Data

• Annual Dividend: $2.32 per share

• Dividend Yield: 2.55%

• Ex-Dividend Date: 27 February 2026

• Payment Date: 16 March 2026

Valuation The average fair value is $95.80. At a current price of $91.02, the stock trades 5.25% below fair value. The Altman Z-Score is not applicable for utility sector companies.

Financial Health
Revenue in 2025 was $27.48 billion and profit margin stands at 16.48%. The company recently announced a 10% increase in its quarterly dividend. It is rated Steady for value generation. The Beneish M-Score of -2.64 indicates no earnings manipulation concerns.

Why It Suits Long-Term Dividend Investors
NextEra has increased its dividend for over 25 consecutive years and has guided for continued dividend growth through 2026. Its renewable energy leadership positions it well for long-term infrastructure investment themes tied to AI data centre power demand and electrification trends.

8. Merck (MRK)

Sector: Healthcare | Exchange: NYSE

Merck is a global pharmaceutical company whose primary revenue drivers include KEYTRUDA, which generated $25.0 billion in sales in 2023, and GARDASIL, which contributed $8.9 billion. It is rated Robust for capital management.

Dividend Data

• Annual Dividend: $3.28 per share

• Dividend Yield: 2.83%

• Shareholders Yield: 14.5%

• Ex-Dividend Date: 16 March 2026

• Payment Date: 7 April 2026

Valuation
The average fair value is $114.89. At a current price of $115.79, the stock trades just 0.77% above fair value, making it the most fairly priced stock on this list relative to intrinsic estimates.

Financial Health
Profit margin is 32.41% and return on equity is 37.17%. The shareholders yield of 14.5% is the highest on this list, reflecting an aggressive share buyback programme. The Beneish M-Score of -3.72 indicates no evidence of earnings manipulation. Recent insider purchases in early 2025 provide a positive signal.

Why It Suits Long-Term Dividend Investors
Merck combines a meaningful dividend yield with an exceptionally high shareholders yield, driven by substantial buybacks. The KEYTRUDA oncology franchise provides a dominant near-term revenue engine, while a deep pipeline supports longer-term income sustainability.

9. Medtronic (MDT)

Sector: Healthcare | Exchange: NYSE

Medtronic is a global medical device company headquartered in Dublin, Ireland. Its four business segments cover cardiovascular, neuroscience, medical surgical, and diabetes products. It is rated Robust for capital management.

Dividend Data

• Annual Dividend: $2.13 per share

• Dividend Yield: 2.34%

• Shareholders Yield: 4.66%

• Ex-Dividend Date: 27 March 2026

• Payment Date: 17 April 2026

Valuation
The average fair value is $110.65. At a current price of $90.90, the stock trades 21.73% below fair value. The DCF model alone estimates fair value at $133.27.

Financial Health
Revenue has grown consistently from $31.23 billion in 2023 to $33.54 billion in 2025. Profit margin is 16.78%, the debt-to-equity ratio is a low 0.06, and the Piotroski F-Score of 6 reflects sound financial health. The Beneish M-Score of -5.03 is well below the threshold, providing strong confidence in the integrity of reported earnings.

Why It Suits Long-Term Dividend Investors
Medtronic has raised its dividend for over 45 consecutive years and trades at a significant discount to estimated fair value. High switching costs in surgical and cardiac devices support predictable recurring revenue, which underpins the dividend commitment.

10. Ares Capital (ARCC)

Sector: Financial Services | Exchange: NASDAQ

Ares Capital is a Business Development Company (BDC) that provides lending and investment to middle-market businesses. It is one of the largest BDCs in the United States with a market capitalisation of $13.42 billion.

Dividend Data

• Annual Dividend: $1.92 per share

• Dividend Yield: 10.25%

• Ex-Dividend Date: 13 March 2026

• Payment Date: 31 March 2026

Valuation
The average fair value is $23.56. At a current price of $18.74, the stock trades 25.71% below fair value, representing the largest percentage discount to intrinsic value on this list.

Financial Health
Net income is $1.42 billion on revenue of $2.54 billion, producing a profit margin of 57.51%. The Piotroski F-Score of 3 is below average, though standard scoring models are less applicable to BDC structures. The Altman Z-Score is not applicable for financial services companies. Notably, the CEO, COO, CFO, and multiple directors made significant open-market purchases of ARCC stock in late 2025 and early 2026.

Why It Suits Long-Term Dividend Investors
A 10.25% yield is the standout feature for income investors. BDCs are structured to distribute the majority of their taxable income as dividends, making ARCC a high-yield vehicle by design rather than by distress. Investors should be aware that BDC dividends can fluctuate with credit cycle conditions and interest rate movements.

Disclaimer: The information provided in this article is for educational purposes only and should not be considered financial or investment advice. All figures including AUM, expense ratios, dividend yields, and performance data were accurate at the time of writing in March 2026 and are subject to change daily with market conditions.